Evidence map›Paper›PMID 28730419›Full record

ReviewEndocrine2017

The intriguing connections of leptin to hyperparathyroidism.

Stergios A Polyzos, Leonidas Duntas, Jens Bollerslev

Abstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Endocrine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Leptin regulates parathyroid hormone secretion through CaSR-ERK1/2 signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Stergios A PolyzosFirst Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. stergios@endo.gr.ORCID http://orcid.org/0000-0001-9232-4042
Leonidas DuntasEndocrine Unit, Evgenidion Hospital, University of Athens, Athens, Greece.
Jens BollerslevSection of Specialized Endocrinology, Medical Clinic B, Oslo University Hospital, Oslo, Norway.
Aristotle University of Thessaloniki · GRNational and Kapodistrian University of Athens · GROslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLeptin has been implicated in bone metabolism, but the association with parathyroid gland function has not been fully clarified. This review aimed to summarize evidence of the association between leptin and hyperparathyroidism, both primary and secondary, elucidating the potential pathophysiologic and therapeutic consequences between leptin and parathyroid hormone, hopefully prompting the design of new studies.

resultsExperimental studies indicate a positive loop between leptin and parathyroid hormone in primary hyperparathyroidism. Dissimilar, parathyroid hormone seems to inhibit leptin expression in severe secondary hyperparathyroidism. Data from clinical studies indicate higher leptin levels in patients with primary hyperparathyroidism than controls, but no association between parathyroid hormone and leptin levels, as well as a minimal or neutral effect of parathyroidectomy on leptin levels in patients with primary hyperparathyroidism. Clinical data on secondary hyperparathyroidism, mainly derived from patients with chronic kidney disease, indicate a potential inverse association between leptin and parathyroid hormone in some, but not all studies. This relationship may be affected by the diversity of morbidity among these patients.

conclusionsData from experimental studies suggest a different association between leptin and parathyroid hormone in primary and secondary hyperparathyroidism. Data from clinical studies are conflicting and potentially affected by confounders. More focused, well-designed studies are warranted to elucidate a potential association between leptin and parathyroid hormone, which may have specific clinical implications, i.e., targeting obesity and hyperleptinemia in patients with hyperparathyroidism.

Indexed as

Models, BiologicalAdipose Tissue, WhiteAnimalsAnti-Obesity AgentsChief Cells, GastricHormone Replacement TherapyHumansHyperparathyroidism, PrimaryHyperparathyroidism, SecondaryInsulin ResistanceLeptinObesityParathyroid GlandsParathyroid HormoneRecombinant ProteinsReproducibility of ResultsAnti-Obesity AgentsLeptinParathyroid HormonePTH protein, humanRecombinant ProteinsLeptinObesityParathyroid glandsParathyroid hormonePrimary hyperparathyroidismSecondary hyperparathyroidism

Identifiers

PMID28730419
OpenAlexW2737234715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.